Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Mayo Clinic ProceedingsREFERENCES
- Neuropathic pain: redefinition and a grading system for clinical research purposes.Neurology. 2008; 70: 1630-1635
- Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey.J Pain. 2005; 6: 356-363
- Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives.J Pain. 2006; 7: 892-900
- The burden of neuropathic pain: results of a cross-sectional survey.Eur J Pain. 2006; 10: 127-135
- The impact of neuropathic pain on health-related quality of life: review and implications.Neurology. 2007; 68: 1178-1182
- Neuropathic pain: a review of the quality of life impact, costs, and cost-effectiveness of therapy.Pharmacoeconomics. 2009; 27: 95-112
- Clinical characteristics and economic costs of patients with painful neuropathic disorders.J Pain. 2004; 5: 143-149
- Health care costs of acute and chronic pain associated with a diagnosis of herpes zoster.J Am Geriatr Soc. 2007; 55: 1168-1175
Dworkin RH, Malone DC, Panarites CJ, Armstrong EP, Pham SV. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs [published online ahead of print October 21, 2009]. J Pain. doi:10.1016/j.jpain. 2009.08.005.
- Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales.Vaccine. 2009; 27: 1454-1467
- The 2008 report of the Chief Medical Officer:150 years of the Annual Report of the Chief Medical Officer: on the state of public health 2008. Department of Health, London, England2009 (Accessed January 12, 2010.)
- Pharmacologic management of neuropathic pain: evidence-based recommendations.Pain. 2007; 132: 237-251
- EFNS guidelines on pharmacological treatment of neuropathic pain.Eur J Neurol. 2006; 13: 1153-1169
- Pharmacological management of chronic neuropathic pain—consensus statement and guidelines from the Canadian Pain Society.Pain Res Manag. 2007; 12: 13-21
- Treatment of neuropathic pain: an overview of recent guidelines.Am J Med. 2009; 122: S22-S32
- Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion?.Pain. 2008; 138: 343-353
- A cross sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: differences in demographic data and sensory systems.Pain. 2009; 146: 34-40
- CEBM Web site. Levels of evidence and grades of recommendation.(Accessed January 12, 2010.)
- AAN-EFNS guidelines on trigeminal neuralgia management.Eur J Neurol. 2008; 15: 1013-1028
- Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies.Neurology. 2008; 71: 1183-1190
- Algorithm for neuropathic pain treatment: an evidence based proposal.Pain. 2005; 118: 289-305
- Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood.Neurology. 1987; 37: 589-596
- Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain.J Palliat Med. 2006; 9: 29-40
- An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.Drug Saf. 2007; 30: 437-455
- The hepatic safety profile of duloxetine: a review.Expert Opin Drug Metab Toxicol. 2008; 4: 281-285
- Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study.Pain. 2004; 110: 697-706
- Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine.Am J Psychiatry. 1997; 154: 1760-1762
- Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief.J Pain. 2008; 9: 1006-1017
- Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin.J Neurol. 2005; 252: 677-686
- Skin biopsy and quantitative sensory testing do not predict response to the lidocaine patch in painful neuropathies.Muscle Nerve. 2006; 33: 42-48
- Morphine versus mexiletine for treatment of postamputation pain.Anesthesiology. 2008; 109: 289-296
- Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial.Neurology. 2002; 59: 1015-1021
- Recommendations for the appropriate use of opioids for persistent non-cancer pain. British Pain Society, London, England2005 (Accessed January 12, 2010.)
- Addiction to opioids in chronic pain patients: a literature review.Eur J Pain. 2007; 11: 490-518
- Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.J Pain. 2009; 10: 113-130
- Clinical trial outcome in neuropathic pain: relationship to study characteristics.Neurology. 2008; 70: 263-272
- Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen.Pain. 2008; 136: 150-157
- Tramadol in neuropathic pain after spinal cord injury: a randomized, double-blind, placebo-controlled trial.Clin J Pain. 2009; 25: 177-184
- Pain associated with multiple sclerosis: systematic review and proposed classification.Pain. 2008; 137: 96-111
- Should cannabinoids be used as analgesics for neuropathic pain?.Nat Clin Pract Neurol. 2008; 4: 654-655
- Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin.Pain. 2007; 130: 76-83
- Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.Ann Neurol. 2008; 64: 274-284
- Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial.Neurology. 2009; 72: 1473-1478
- CHMP assessment report for Qutenza.(Accessed January 12, 2010.)
- NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study.Lancet Neurol. 2008; 7: 1106-1112
- Full prescribing information.(Accessed January 12, 2010.)
- Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy.Neurology. 2008; 70: 2305-2313
- The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy.Brain. 2004; 127: 1606-1615
- Roles of capsaicin-in-sensitive nociceptors in cutaneous pain and secondary hyperalgesia.Brain. 2001; 124: 1754-1764
- Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study.Clin J Pain. 2007; 23: 150-158
- Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial.J Pain. 2009; 10: 818-828
- Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens.Clin J Pain. 2009; 25: 376-385
- Clinical study summary (CSS) template, Study No. SP874.(Accessed January 12, 2010.)
Hidvégi T, Bretschneider B, Thierfelder S, Sommerville K, Bongardt S. Long-term efficacy of lacosamide in subjects with diabetic neuropathic pain: results of a double-blind, randomized withdrawal trial. Presented at: 27th annual meeting of the American Pain Society; Tampa, FL; May 8-10, 2008.
- Clinical study summary (CSS) template, Study No. SP743.(Accessed January 12, 2010.)
- The need for improved access to FDA reviews.JAMA. 2009; 302: 191-193
- Long-term oral lacosamide in painful diabetic neuropathy: a two-year open-label extension trial.Eur J Pain. 2009; 13: 458-463
- The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms.Pain. 1990; 42: 135-144
- The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy.Clin Pharmacol Ther. 1992; 52: 547-552
- Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.N Engl J Med. 1992; 326: 1250-1256
- Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial.Pain. 2008; 139: 275-283
- Morphine, gabapentin, or their combination for neuropathic pain.N Engl J Med. 2005; 352: 1324-1334
- Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.Eur J Pain. 2008; 12: 804-813
Zin CS, Nissen LM, O'Callaghan JP, Duffull SB, Smith MT, Moore BJ. A randomized controlled trial of oxycodone vs placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin [published online ahead of print December 2, 2009]. J Pain. doi:10.1016/j. jpain.2009.09.003.
- Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study.Eur Neurol. 2009; 61: 129-137
- Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial.Lancet. 2009; 374: 1252-1261
- Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy.Curr Med Res Opin. 2009; 25: 1677-1687
- Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: a prospective double-blind randomized placebo-controlled study.Diabetes Res Clin Pract. 2009; 83: 371-378
- Randomized clinical trials of pregabalin for neuropathic pain: methods, results, and implications.Progr Neurotherapeutics Neuropsychopharmacol. 2008; 3: 167-187
- Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain.Pain. 2007; 130: 66-75
- Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials.Acta Neurol Scand. 2004; 110: 221-231
- Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study.Acta Neurol Scand. 2006; 113: 395-404
- A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis.Clin Ther. 2007; 29: 2022-2030
- Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain.J Pain Symptom Manage. 2007; 34: 446-454
- Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized double-blind, placebo-controlled studies.Pain. 2007; 128: 169-179
Simpson DM, Schifitto G, Clifford DB, et al. 1066 HIV Neuropathy Study Group. Pregabalin in the treatment of painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Poster presented at: 61st Annual Meeting of the American Academy of Neurology, Seattle, WA; April 29, 2009.
- Phase II results for GSK1838262 (XP13512) reported for neuropathic pain associated with diabetic peripheral neuropathy. XenoPort, Inc, Santa Clara, CA2009
- Animal models and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards.Pain. 2008; 139: 243-247
- Pharmacological treatment of peripheral neuropathic conditions based on shared commonalities despite multiple etiologies.Pain. 2005; 113: 251-254
- A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection.Neurology. 1998; 51: 1682-1688
- Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial.JAMA. 1998; 280: 1590-1595
- A randomized controlled trial of 5% lidocaine gel for HIV-associated distal symmetric polyneuropathy.J Acquir Immune Defic Syndr. 2004; 37: 1584-1586
- A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy.J Neurovirol. 2006; 12: 328-331
- Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy.Pain. 2002; 98: 195-203
- Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms.J Pain Symptom Manage. 2008; 35: 31-39
- Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).Cancer. 2007; 110: 2110-2118
- PhRMA web synopsis (Protocol A0081007): a randomized placebo-controlled trial of the efficacy and safety of pregabalin in the treatment of subjects with neuropathic pain associated with lumbo-sacral radiculopathy.(Accessed January 12, 2010.)
- Topiramate in chronic lumbar radicular pain.J Pain. 2005; 6: 829-836
- EFNS guidelines on neurostimulation therapy for neuropathic pain.Eur J Neurol. 2007; 14: 952-970
- Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects.Neurology. 2004; 63: 865-873
- Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain.Neurology. 2005; 65: S7-S19
- Methodological issues in clinical trials of opioids for chronic pain.Neurology. 2005; 65: S32-S49
- Placebo response in neuropathic pain trials.Pain. 2008; 138: 479-483
- Enriched enrollment randomized withdrawal trial designs for analgesics.Clin J Pain. 2009; 25: 797-807
- Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations.J Pain. 2008; 9: 105-121
- Interpreting treatment effects in randomised trials.BMJ. 1998; 316: 690-693
- Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations.Pain. 2009; 146: 238-244
- Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic neuropathy pain.Arch Intern Med. 1999; 159: 1931-1937
- Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial—the GONIP trial.Int J Clin Pharmacol Ther. 2006; 44: 358-363
- Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial.Clin Drug Investig. 2009; 29: 231-241
- 5% Lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study.Curr Med Res Opin. 2009; 25: 1663-1676
- Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury.Arch Phys Med Rehabil. 2007; 88: 1547-1560
- Toward a definition of pharmacoresistant neuropathic pain.Eur J Pain. 2009; 13: 439-440
- Randomised Controlled Trials: Questions, Answers and Musings. 2nd ed. Blackwell/BMJ Books, London, England2007
- A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.N Engl J Med. 2005; 352: 2271-2284
- Persistent postsurgical pain: risk factors and prevention.Lancet. 2006; 367: 1618-1625
- Pain: moving from symptom control toward mechanism-specific pharmacologic management.Ann Intern Med. 2004; 140: 441-451
- Mechanisms of neuropathic pain and their implications for the design of clinical trials.Neurology. 2005; 65: S66-S73
- Difficulties in stratifying neuropathic pain by mechanisms.Eur J Pain. 2003; 7: 353-357
- Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values.Pain. 2006; 123: 231-243
- Quantitative sensory testing: a comprehensive protocol for clinical trials.Eur J Pain. 2006; 10: 77-88
- A novel tool for the assessment of pain: validation in low back pain.PLoS Med. 2009; 6: e1000047https://doi.org/10.1371/journal.pmed.1000047
- Customizing treatment for chronic pain patients: who, what and why?.Clin J Pain. 1990; 6: 255-270
Article info
Footnotes
Support for the meeting on which this article is based and article preparation was provided by an unrestricted grant from Endo Pharmaceuticals to the University of Rochester Office of Continuing Professional Education, from which all authors received honoraria for their participation. Individual disclosures can be found on page S11.
Individual Disclosures for Authors: Dr Dworkin has received in the past 12 months research support from Arcion, Montel Williams Foundation, and NeurogesX and consulting fees from Allergan, Astellas, AstraZeneca, Boehringer Ingelheim, Durect, Eisai, Endo Pharmaceuticals, Epicept, Forest, Genzyme, Johnson & Johnson, Eli Lilly, Michael J. Fox Foundation for Parkinson's Research, NeurogesX, Nuvo, Pfizer, PainReform, Philips Respironics, Sanofi Aventis, Solace, Solvay, Spinifex, UCB Pharma, US Department of Veterans Affairs, US National Institutes of Health, Wyeth, and Xenon; Dr O'Connor has no financial arrangement or affiliation with a corporate organization or a manfacturer of a product discussed in this supplement; Dr Audette has served on the speakers' bureau for Allergan, Endo Pharmaceuticals, and Johnson & Johnson; Dr Baron has received grant/research support from Pfizer Pharma, Genzyme, and Grünenthal and has served on the speakers' bureau and as a consultant for Pfizer Pharma, Genzyme, Grünenthal, Mundipharma, Allergan, Sanofi Pasteur, Astellas, Eisai, Medtronic, USB, and Eli Lilly; Dr. Gourlay has no financial arrangement or affiliation with a corporate organization or a manfacturer of a product discussed in this supplement; Dr Haanpää has served as consultant for Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly, Medtronic, MSD, Mundipharma, Orion, Pfizer, and Sanofi Pasteur and is a permanent assessor of EMEA; Dr Kent has received grant/research support from GlaxoSmithKline and has served on the speakers' bureau for Medtronic; Dr Krane has no financial arrangement or affiliation with a corporate organization or a manfacturer of a product discussed in this supplement; Dr LeBel has no financial arrangement or affiliation with a corporate organization or a manfacturer of a product discussed in this supplement; Dr Levy has received grant/research support from St. Jude Medical Neuromodulation, has served as a consultant for Bioness, Codman, Medtronic, St Jude Medical Neuromodulation, and Stryker; Dr Mackey has no financial arrangement or affiliation with a corporate organization or a manfacturer of a product discussed in this supplement; Dr Mayer has received grant/research support from Johnson & Johnson and is on the Clinical Advisory Board for Palladian Health; Dr Miaskowski has no financial arrangement or affiliation with a corporate organization or a manfacturer of a product discussed in this supplement; Dr Raja has received grant/research support from Allergan and Medtronic and served as a consultant for Allergan, Alpharma (King), Schering-Plough, and Solvay; Dr Rice has received grant/research support from Pfizer and Spinifex and has served as a consultant for Pfizer, Allergen, Astellas, Daiichi Sankyo, GlaxoSmithKline, NeurogesX, Spinifex, and Eisia; Dr Schmader has received grant/research support from Merck and Wyeth and has served as a consultant for Merck and GlaxoSmithKline; Dr Stacey has received grant/research support from AstraZeneca and has served as a consultant for GlaxoSmithKline, Boehringer Ingelheim, Boston Scientific, Eli Lilly, Niktar, QRX Pharma, Pfizer, AstraZeneca, and Xenon; Dr Stanos has received grant/research support from Ortho-McNeil; has served as a consultant for Abbott Labs, Eli Lilly, Endo Pharmaceuticals, King, and Ortho-McNeil; and is on the speakers' bureau for Endo Pharmaceuticals, Eli Lilly, Ortho-McNeil, Pfizer, King, and Forest; Dr Treede has received grant/research support from Kade and Boehringer Ingelheim and has served as a consultant for Grünenthal, UCB, AWD pharma, GmbH & Co, and Kade; Dr Turk has received grant/research support from Endo Pharmaceuticals, Johnson & Johnson, and Philips Respironics and has served as a consultant for Eli Lilly, Johnson & Johnson, Philips Respironics, and SK Lifescience; Dr Walco has served as a consultant for Neuromed, Pfizer, and Purdue Pharma; Dr Wells has served as a consultant for Prostrachan and is on the speakers' bureau for Grünenthal, Napp (Purdue in the United States), and Pfizer.
